Synergistic induction of cell death in liver tumor cells by TRAIL and chemotherapeutic drugs via the BH3-only proteins Bim and Bid

Cell Death and Disease

Volumn 1, Issue 10, 2010, Pages

  Schneider Jakob, S ^a   Corazza, N ^a   Badmann, A ^a   Sidler, D ^a   Stuber Roos, R ^a   Keogh, A ^a   Frese, S ^a   Tschan, M ^a   Brunner, T ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Bcl 2 homologs; Death receptor; Hepatocytes; Jun kinase; Liver tumors; Mitochondria; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; BIM PROTEIN; PROTEIN BID; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; APOPTOSIS REGULATORY PROTEIN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; DOXORUBICIN; MEMBRANE PROTEIN; ONCOPROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE THERAPY; HUMAN; HUMAN CELL; LIVER CELL CULTURE; LIVER TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; CELL STRAIN HEPG2; DRUG POTENTIATION; METABOLISM; MITOCHONDRION; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; DOXORUBICIN; DRUG SYNERGISM; HEP G2 CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER NEOPLASMS; MEMBRANE PROTEINS; MITOCHONDRIA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79958698544     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2010.66     Document Type: Article

References (45)

1. Gerl R, Vaux DL. Apoptosis in the development and treatment of cancer. Carcinogenesis 2005; 26: 263-270. (Pubitemid 40246548)
2. Schulze-Bergkamen H, Krammer PH. Apoptosis in cancer-implications for therapy. Semin Oncol 2004; 31: 90-119.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
4. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
5. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163. (Pubitemid 29068521)
6. Frese S, Brunner T, Gugger M, Uduehi A, Schmid RA. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg 2002; 123: 168-174.
7. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002; 62: 5800-5806. (Pubitemid 35204738)
8. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 2003; 63: 4713-4723. (Pubitemid 36951052)
9. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001; 8: 1066-1075. (Pubitemid 33061824)
10. Wu GS, Burns TF, McDonald III ER, Jiang W, Meng R, Krantz ID et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141-143.
11. Vivo C, Liu W, Broaddus VC. c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J Biol Chem 2003; 278: 25461-25467. (Pubitemid 36835297)
12. Corazza N, Jakob S, Schaer C, Frese S, Keogh A, Stroka D et al. TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J Clin Invest 2006; 116: 2493-2499. (Pubitemid 44330148)
13. Kaufmann T, Jost PJ, Pellegrini M, Puthalakath H, Gugasyan R, Gerondakis S et al. Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity 2009; 30: 56-66.
14. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22: 8628-8633. (Pubitemid 38019198)
15. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999; 3: 287-296. (Pubitemid 29290669)
16. Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003; 100: 2432-2437. (Pubitemid 36297516)
17. Putcha GV, Le S, Frank S, Besirli CG, Clark K, Chu B et al. JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron 2003; 38: 899-914. (Pubitemid 36782382)
18. Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and posttranslational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002; 9: 505-512. (Pubitemid 34521178)
19. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856-859.
20. Czabotar PE, Lee EF, van DelftMF, Day CL, Smith BJ, Huang DC et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci USA 2007; 104: 6217-6222. (Pubitemid 47186075)
21. Kaufmann T, Tai L, Ekert PG, Huang DC, Norris F, Lindemann RK et al. The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell 2007; 129: 423-433. (Pubitemid 46574974)
22. Yin X,Wang K, Gross A, Zhao Y, Zinkel S, Klocke B et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999; 400: 886-891. (Pubitemid 29406726)
23. Martin SJ, Green DR. Apoptosis as a goal of cancer therapy. Curr Opin Oncol 1994; 6: 616-621. (Pubitemid 24347338)
24. Terradillos O, Pollicino T, Lecoeur H, Tripodi M, Gougeon ML, Tiollais P et al. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene 1998; 17: 2115-2123. (Pubitemid 28499338)
25. Weiland T, Weiller M, Kunstle G, Wendel A. Sensitization by 5-azacytidine toward death receptor-induced hepatic apoptosis. J Pharmacol Exp Ther 2009; 328: 107-115.
26. Koschny R, Holland H, Sykora J, Erdal H, Krupp W, Bauer M et al. Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis. J Neurooncol 2010; 97: 171-185.
27. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564-567. (Pubitemid 30305907)
28. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995; 15: 3032-3040.
29. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000; 19: 1735-1743. (Pubitemid 30200979)
30. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006; 12: 2640-2646.
31. Lacour S, Hammann A, Grazide S, Lagadic-Gossmann D, Athias A, Sergent O et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res 2004; 64: 3593-3598. (Pubitemid 38657937)
32. Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L et al. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 2005; 106: 4131-4138. Epub 2005 Aug 4123. (Pubitemid 41775918)
33. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003; 162: 613-622. (Pubitemid 37022939)
34. Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, Burgering BM et al. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 2002; 168: 5024-5031. (Pubitemid 34495965)
35. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 2001; 29: 629-643. (Pubitemid 32323937)
36. Bianchini R, Nocentini G, Krausz LT, Fettucciari K, Coaccioli S, Ronchetti S et al. Modulation of pro- and antiapoptotic molecules in double-positive (CD4+CD8+) thymocytes following dexamethasone treatment. J Pharmacol Exp Ther 2006; 319: 887-897.
37. Bouillet P, Purton JF, Godfrey DI, Zhang LC, Coultas L, Puthalakath H et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 2002; 415: 922-926. (Pubitemid 34174755)
38. Hubner A, Barrett T, Flavell RA, Davis RJ. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell 2008; 30: 415-425. (Pubitemid 351672377)
39. Michalak EM, Villunger A, Adams JM, Strasser A. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ 2008; 15: 1019-1029. (Pubitemid 351712606)
40. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907-14912. (Pubitemid 44527827)
41. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982; 42: 3858-3863. (Pubitemid 12054507)
42. Nguyen TH, Mai G, Villiger P, Oberholzer J, Salmon P, Morel P et al. Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes. J Hepatol 2005; 43: 1031-1037. (Pubitemid 41627989)
43. Strain AJ, Ismail T, Tsubouchi H, Arakaki N, Hishida T, Kitamura N et al. Native and recombinant human hepatocyte growth factors are highly potent promoters of DNA synthesis in both human and rat hepatocytes. J Clin Invest 1991; 87: 1853-1857.
44. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995; 182: 1545-1556.
45. Adrain C, Creagh EM, Martin SJ. Apoptosis-associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J 2001; 20: 6627-6636. (Pubitemid 33134193)